General Information of Synthetic Binding Protein (SBP) (ID: SBP003384)
SBP Name
scFv Radretumab
Synonyms
TAB-193; L19-131 I; L19-I131; L19-SIP
Molecular Weight 38.6 kDa
Design Method Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status Phase II; Discontinued
Sequence Length 357
SBP Sequence
>scFv Radretumab
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSSGDGS
SGGSGGASEIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYA
SSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIKSGGS
GGPRAAPEVYAFATFEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPR
KTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPESSRRGGC
3D Structure
Computationally Modelled Structure
Click to Save PDB File
Protein Scaffold Information of This SBP
Scaffold ID PS057
Scaffold Info
[1]
Scaffold Name scFv
Scaffold Class Antibody fragment
Fold Type Beta-Sheets + Loops
Binding Target(s) of This SBP (BTS)
BTS Name Details Mechanism Application Affinity Research Organization Ref
Fibronectin
BTS Info
Inhibitor Brain cancer [ICD-11: 2A00.5]; Haematological malignancies [ICD-11: 2B33.Y]; Hodgkin lymphoma [ICD-11: 2B30.Z]; Non-small cell lung cancer [ICD-11: 2C25.Y]; Solid tumour/cancer [ICD-11: 2A00-2F9Z] N.A. Philogen [1]
References
1 Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.